Your browser doesn't support javascript.
loading
AI-MARRVEL - A Knowledge-Driven AI System for Diagnosing Mendelian Disorders.
Mao, Dongxue; Liu, Chaozhong; Wang, Linhua; Ai-Ouran, Rami; Deisseroth, Cole; Pasupuleti, Sasidhar; Kim, Seon Young; Li, Lucian; Rosenfeld, Jill A; Meng, Linyan; Burrage, Lindsay C; Wangler, Michael F; Yamamoto, Shinya; Santana, Michael; Perez, Victor; Shukla, Priyank; Eng, Christine M; Lee, Brendan; Yuan, Bo; Xia, Fan; Bellen, Hugo J; Liu, Pengfei; Liu, Zhandong.
Afiliación
  • Mao D; Department of Pediatrics, Baylor College of Medicine, Houston.
  • Liu C; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston.
  • Wang L; Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston.
  • Ai-Ouran R; Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston.
  • Deisseroth C; Graduate School of Biomedical Sciences, Program in Quantitative and Computational Biosciences, Baylor College of Medicine, Houston.
  • Pasupuleti S; Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston.
  • Kim SY; Graduate School of Biomedical Sciences, Program in Quantitative and Computational Biosciences, Baylor College of Medicine, Houston.
  • Li L; Department of Pediatrics, Baylor College of Medicine, Houston.
  • Rosenfeld JA; Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston.
  • Meng L; Department of Data Science and AI, Al Hussein Technical University, Amman, Jordan.
  • Burrage LC; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston.
  • Wangler MF; Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston.
  • Yamamoto S; Department of Pediatrics, Baylor College of Medicine, Houston.
  • Santana M; Department of Pediatrics, Baylor College of Medicine, Houston.
  • Perez V; Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston.
  • Shukla P; Department of Pediatrics, Baylor College of Medicine, Houston.
  • Eng CM; Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston.
  • Lee B; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston.
  • Yuan B; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston.
  • Xia F; Baylor Genetics, Houston7.
  • Bellen HJ; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston.
  • Liu P; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston.
  • Liu Z; Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston.
NEJM AI ; 1(5)2024 May.
Article en En | MEDLINE | ID: mdl-38962029
ABSTRACT

BACKGROUND:

Diagnosing genetic disorders requires extensive manual curation and interpretation of candidate variants, a labor-intensive task even for trained geneticists. Although artificial intelligence (AI) shows promise in aiding these diagnoses, existing AI tools have only achieved moderate success for primary diagnosis.

METHODS:

AI-MARRVEL (AIM) uses a random-forest machine-learning classifier trained on over 3.5 million variants from thousands of diagnosed cases. AIM additionally incorporates expert-engineered features into training to recapitulate the intricate decision-making processes in molecular diagnosis. The online version of AIM is available at https//ai.marrvel.org. To evaluate AIM, we benchmarked it with diagnosed patients from three independent cohorts.

RESULTS:

AIM improved the rate of accurate genetic diagnosis, doubling the number of solved cases as compared with benchmarked methods, across three distinct real-world cohorts. To better identify diagnosable cases from the unsolved pools accumulated over time, we designed a confidence metric on which AIM achieved a precision rate of 98% and identified 57% of diagnosable cases out of a collection of 871 cases. Furthermore, AIM's performance improved after being fine-tuned for targeted settings including recessive disorders and trio analysis. Finally, AIM demonstrated potential for novel disease gene discovery by correctly predicting two newly reported disease genes from the Undiagnosed Diseases Network.

CONCLUSIONS:

AIM achieved superior accuracy compared with existing methods for genetic diagnosis. We anticipate that this tool may aid in primary diagnosis, reanalysis of unsolved cases, and the discovery of novel disease genes. (Funded by the NIH Common Fund and others.).

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: NEJM AI Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: NEJM AI Año: 2024 Tipo del documento: Article